Company profile
ArriVent BioPharma, Inc.
NASDAQ: AVBP · Healthcare · Biotechnology
PublicHQ Newtown Square, PACIK 0001868279Reports USD
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH 57DQ —GM —SS 50
v0.1 · 35/100 weight · pillars only
↑ Altman-Z, balance-sheet leverage · ↓ Piotroski F, listing tenure
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$166.3M
Employees
77
as of 2026-09-10
Market cap
$1.4B
as of 2026-09-10
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$166.3M-$166.3M2025
Operating income-$177.5M-$177.5M2025
Total assets$333.2M$333.2M2025
Liabilities$25.9M$25.9M2025
Equity$307.2M$307.2M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is ArriVent BioPharma, Inc.’s financial profile?
ArriVent BioPharma, Inc. earned -$166.3M in FY2025 net income.
Peers · Healthcare
Bicara Therapeutics Inc. Common Stock——Avalyn Pharma Inc. Common Stock——First Tracks Biotherapeutics Inc——Latigo Biotherapeutics Inc.——Aktis Oncology, Inc.——LB Pharmaceuticals Inc Common Stock——Key facts
CEOZhengbin Yao
SectorHealthcare
IndustryBiotechnology
HeadquartersNewtown Square, PA
ExchangeNASDAQ: AVBP
Employees77
IPO date2024-01-26
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.